Ninety-day repeated oral toxicity study of saponified Capsicum annum fruit extract with 50% capsanthin in Sprague-Dawley Rats with a 28-day recovery period

Velmurugan Shanmugham *, Ravi Subban

Department of Chemistry, Karpagam Academy of Higher Education, Coimbatore 641021, India

**A R T I C L E   I N F O**

Handling Editor: DR. Aristidis Tsatsakis

Keywords:
Saponified Capsicum annum fruit extract
Capsicum annum
Capsanthin 50% w/w
Toxicity
SD Rats
NOAEL

**A B S T R A C T S**

A ninety-day oral toxicity study of saponified Capsicum annum fruit extract with 50% (w/w) capsanthin (SCFE-50 C) was performed by oral gavage administration to male and female Sprague-Dawley (SD) rats at doses of 0, 500, 1000 and 2000 mg/kg BW/day for a period of ninety consecutive days. To assess the reversal of toxicity, the treatment phase was followed with a twenty-eight-day recovery period. The treatment with SCFE-50 C in both male and female SD rats showed no mortality, and no treatment-related toxicologically significant changes were observed in any groups. No significant differences between treated and control groups were found in feed consumption, body weight gain, individual organ weights, ocular examination, clinical chemistry or blood biochemistry. The necroscopy and histopathology examination did not reveal any clinically significant changes in male and female rats from the 2000 mg/kg BW/day group. According to this study, the no observable adverse effect level (NOAEL) for saponified Capsicum annum fruit extract with 50% (w/w) capsanthin (SCFE-50 C) administered by oral gavage for 90-days is > 2000 mg/kg BW/day in SD rats.

1. Introduction

Capsanthin (CAS 462-42-9) is a pepper-derived, lipophilic carotenoid, mostly found in the pericarp of ripe red pepper (capsicum spp.) and that is synthesized during carotenogenesis [1]. Capsanthin (3R,3′,5′R)-3,3′-dihydroxybeta,kappa-caroten-6-one has the molecular formula C40H40O3 and the molecular weight of 584.87 g/mol [2]. Capsanthin, a biological antioxidant, is a major carotenoid found in the red pepper to a maximum amount of 60% (w/w) of the total carotenoids [3]. Biological antioxidants can be classified into two major groups such as preventive and chain-breaking antioxidants. The role of preventive antioxidants is to suppress the chain-initiating radicals and thereby reducing lipid peroxidation whereas the chain-breaking antioxidants inhibit the formation of peroxide radicals [4]. Carotenoids can act as both preventive as well as chain-breaking antioxidants. In the preventive action, it quenches singlet oxygen and in chain-breaking, it suppresses the lipid peroxidation [5]. The phospholipids can be protected from oxidative damage by the chain-breaking action of carotenoids [6]. Capsanthin and capsanthin enriched paprika extract potentially inhibits colon carcinogenesis [7]. In a carbon tetrachloride-induced hepatotoxicity model, capsanthin conserved significant level of superoxide dismutase in carbon tetrachloride treated rats [8].

Capsanthin reduces the formation of malondialdehyde (MDA), which is one of the most known secondary products of lipid peroxidation and is used as a cell membrane injury marker [9]. In a Cu2+ catalyzed oxidation study, the LDL oxidation, and formation of dienes were suppressed by capsanthin. It also lowers LDL fraction and inhibits the auto-oxidation of cholesterol [10]. Saponified Capsicum annum fruit

**Abbreviations:** BW, Body weight; MCH, Mean Corpuscular Haemoglobin; ALB, Albumin; MCHC, Mean Corpuscular Haemoglobin Concentration; ALP, Alkaline phosphatase; MCV, Mean Corpuscular Volume; ALT, Alanine Aminotransferase; MON, Monocytes; APTT, Activated partial thromboplastin time; Na, Sodium; AST, Aspartate Aminotransferase; NEU, Neutrophils; BAS, Basophils; NOAEL, No Observed Adverse Effect Level; BUN, Blood Urea Nitrogen; PHO, Phosphate; Ca, Calcium; PLT, Platelet; Cl, Chloride; PT, Partial Thromboplastin time; CRE, CreatinineRBC, Erythrocyte count; EOS, Eosinophils; Retic, Reticulocytes; FBW, Fasting Body Weight; SD, Sprague-Dawley; GGT, Gamma Glutamyl Transpeptidase; T3, Triiodothyronine; GLOB, Globulin; T4, Thyroxine; Glu, Glucose; TBA, Total bile acids; HCT, Haematocrit; TBIL, Total Bilirubin; HDL, High Density Lipoprotein; TCHO, Total Cholesterol; HGB, Hemoglobin; TP, Total protein; K, Potassium; TRIG, Triglycerides; LDL, Low Density Lipoprotein; TSH, Thyroxine stimulating Hormone; LYM, Lymphocytes; WBC, Total leukocyte count.

* Corresponding author.

E-mail address: vp@biogenero.in (V. Shanmugham).
Table 1
Specification of SCFE-50 C.

| Parameter             | Specification                  | Protocol           |
|-----------------------|--------------------------------|--------------------|
| **Physical**          |                                |                    |
| Description           | Dark red powder with characteristic odor | Organoleptic        |
| Identification        | To comply by HPLC and UV        | HPLC and UV        |
| Solubility            | Soluble in organic solvents and insoluble in water |                    |
| Loss on drying        | Not more than 5.0%              | USP < 561 >        |
| **Chemical**          |                                |                    |
| Assay                 | Capsinanth by HPLC              | HPLC               |
|                      | Total Carotenoids by UV         | UV                 |
| **Others**            |                                |                    |
| Lead                  | Not more than 5.0 ppm           | ICP-OES            |
| Arsenic               | Not more than 3.0 ppm           | ICP-OES            |
| Cadmium               | Not more than 1.0 ppm           | ICP-OES            |
| Mercury               | Not more than 1.0 ppm           | ICP-OES            |
| **Microbiological profile** |                                |                    |
| Total aerobic microbial count | Not more than 3000 cfu/g | USP < 2021 >       |
| Total yeast and mold count | Not more than 100 cfu/g | USP < 2021 >       |
| Escherichia coli      | Negative/10 g                   | USP < 2022 >       |
| Salmonella            | Negative/10 g                   | USP < 2022 >       |
| Staphylococcus aureus | Negative/10 g                   | USP < 2022 >       |
| Pseudomonas aeruginosa| Negative/10 g                   | USP < 62 >         |

UV: Ultraviolet spectrophotometer, USP: United States Pharmacopeia, ICP-OES: Inductively coupled plasma-Optical emission spectroscopy, HPLC: High performance Liquid chromatography.

UV spectrophotometer: make-Shimadzu, Japan. Model-1900I. Instrument conditions: multiple wavelength scanning mode (190–800 nm).

HPLC: make-Shimadzu Japan, model: i-series plus LC-2030. Column-Sunfire L1 (Waters, USA). Dimension of 250 × 4.6 mm and particle size 5 µm. Mobile phase-binary gradient consists of acetone as solvent A and water as solvent B. Binary gradient program-0–5 min, 75% B, 5–10 min, 75–95% B, 10–17 min, 95% B, 17–22 min, 95–100% B, 22–25 min, 100–75% B. The total flow rate-1.2 mL/min. Detection wavelength-450 nm. ICP-OES, make-Agilent, USA, Model-5510. Plasma conditions-Argon 15 L/min, Aux gas 0.8–1.0 L/min, analysis mode 500–700kpa. Nebulizer gas-0.7–1.2 L/min. RF power-700–1600 W.

Fig. 1. HPLC chromatogram of capsinanth standard and saponified Capsicum annum fruit extract with 50% w/w capsinanth (SCFE-50 C). Reference standard-capsanthin from Sigma-Aldrich (Cat No. 19081, LOT BCC6238). Instrument-Shimadzu HPLC, i-series plus LC-2030. Column-Sunfire column L1 (Waters, USA). Column dimension-250 × 4.6 mm and particle size 5 µm. The binary gradient consists of acetone as solvent A and water as solvent B and the binary gradient program were 0–5 min, 75% B, 5–10 min, 75–95% B, 10–17 min, 95% B, 17–22 min, 95–100% B, 22–75 min, 100–75% B. Detection wavelength-450 nm. Flow rate-1.2 mL/min. Capsanthin was identified in the SCFE-50 C based on the retention time of the capsinanth in reference standard.

extract is widely used in processed food as an additive [11] and in dietary supplements for Age-related macular diseases (ARMD). In a sub-chronic toxicity study, no adverse effect was observed in rats fed with the saponified paprika extract 10,000 mg/kg feed corresponds to mean dosage of test item 858 mg (41.4 mg total carotenoids)/kg BW/day in males and 879 mg (42.4 mg total carotenoids) /kg BW/day [11]. Low-observed-adverse-effect level (LOAEL) of a pungency-masked and sustained release formulation of capsaicinoids-rich Capsicum annum extract using galactomannan, a soluble dietary fiber from fenugreek was determined for 500 mg/kg BW /day [12]. However, toxicological assessment on saponified extract standardized for > 50% (w/w) capsinanth and > 90% (w/w) total carotenoids has not been done and reported. It is, therefore, necessary to verify the toxicity effects of subchronic use of SCFE-50 C in rats to derive NOAEL. Accordingly, we tested the SCFE-50 C in rats to access the toxicity of its subchronic use.

2. Materials and methods

2.1. Test sample and reagents

2.1.1. Vehicle control and Reagents

Vehicle control corn oil (Cat No. C8267) was procured from Merck (Merck Life Sciences Pvt Ltd, Bangalore, India), n-hexane (CAS 110–54–3, Cat No. 01082), ethyl acetate (CAS 141–78–6, Cat No. 010520) were procured from Spectrochem (Spectrochem Private Limited, Mumbai, India). Potassium hydroxide (CAS 1310–58–3, Cat No. 221473) was procured from Merck (Merck Life Science Pvt Ltd, Bangalore India). Capsanthin reference standard (Cat No. 19081, Lot# BCC6238) was procured from Sigma-Aldrich (Sigma-Aldrich, Inc., St. Louis, USA). Tropicamide 1% Eye drops (Intas Pharmaceuticals, Mumbai, India) procured from a local pharmacy. Hematology analyzer calibration standard Minocal Calibrator (Cat No. 2032002, Lot No. 437) procured from Horiba (Horiba medical, Irvine, USA) and Clinical chemistry analyzer calibration standard Randox L2 (Human sera L2, Cat. No. HS2611, Lot No. 1221UN) procured from Randox (Randox Laboratories, London, England).

2.1.2. Sample preparation

SCFE-50 C was prepared by extracting capsinanth ester from dried Capsicum annum fruits by solvent extraction method using n-hexane as a solvent. It was further purified by SCFE (Super Critical Fluid Extraction). The carotenoid esters were saponified by treating with 40% potassium hydroxide and purified by countercurrent extraction using ethyl acetate and water. The ethyl acetate layer was dried and concentrated under vacuum to obtain Capsicum annum extract which was standardized to contain > 50% (w/w) capsinanth and > 90% (w/w) total carotenoids [13] and complies with pre-determined specification as shown in Table 1. The SCFE-50 C was packed in light resistance low density polyethylene bags, purged with nitrogen, sealed and stored at 5 °C ± 3 °C.

2.1.3. Quantification of capsinanth in SCFE-50 C by HPLC

The quantification of capsinanth was carried out as per the method described in The Joint Expert committee on Food Additives (JECA) capsinanth monograph [14]. Capsanthin was extracted using acetone, saponified and subjected to HPLC. Capsanthin reference standard from Sigma-Aldrich was used for quantification. Shimadzu HPLC, i-series plus LC-2030, (Shimadzu corporation, Kyoto, Japan) and Sunfire column L1 (Waters Corporation, Milford, USA) with a dimension of 250 × 4.6 mm and particle size 5 µm were used. The binary gradient consists of acetone as solvent A and water as solvent B and the binary gradient program were 0–5 min, 75% B, 5–10 min, 75–95% B, 10–17 min, 95% B, 17–22 min, 95–100% B, 22–25 min, 100–75% B. The total flow rate was set at 1.2 mL/min, and the detection wavelength was set at 450 nm. Capsanthin was identified in the samples based on the retention time of the capsanthin reference standard.
A stability study of SCFE-50 C was performed as per ICH guidelines. Packets of 10 g each packed in light resistance Low-density poly bag, purged with nitrogen, and sealed. The samples of SCFE-50 C were kept at 5 ± 3 ºC for 12 months. Physical and chemical parameters were used to assess the stability. The samples were withdrawn and analyzed immediately at room temperature as per protocol (initial, 3, 6, and 12 months) and the data was compared with the initial values. The analytical data indicate that the physical, chemical parameters of SCFE-50 C remained within the specification during the stability period. The variation of the capsanthin content was found to be within the specified limit. The product is stable physically and chemically throughout the accelerated stability study.

UV spectrophotometer: make-Shimadzu, Japan. Model-1900i. Instrument conditions: multiple wavelength scanning mode(190-800 nm).

HPLC: make-Shimadzu Japan, model: i-series plus LC-2030. Column-Sunfire L1 (Waters, USA). Dimension of 250 × 4.6 mm and particle size 5 µm. Mobile phase-binary gradient consists of acetone as solvent A and water as solvent B. Binary gradient program- 0% B, 5 min, 75% B, 5–10 min, 75–95% B, 10–17 min, 95% B, 17–22 min, 95–100% B, 22–75 min, 100–75% B. The total flow rate-1.2 mL/min. Detection wavelength- 450 nm.

### Table 2
Stability of capsanthin content in the sample of saponified Capsicum annum fruit extract with capsanthin 50% w/w (SCFE-50 C) for the duration up to 12 months under the storage temperature 5 ± 3 ºC.

| Period of keeping | Content of capsanthin by HPLC (%) w/w |
|-------------------|--------------------------------------|
|                   | 5% in corn oil | 10% in corn oil | 20% in corn oil |
| Initial           | 5.42          | 10.86          | 20.93           |
| After 1 h         | 5.31          | 10.71          | 20.79           |
| After 2 h         | 5.38          | 10.69          | 20.52           |
| After 3 h         | 5.26          | 10.43          | 20.29           |

A stability study of SCFE-50 C in corn oil was performed at room temperature (25 ± 2 ºC). The 5%, 10%, and 20% w/w SCFE-50 C in corn oil prepared in an amber-colored beaker, covered with a lid, and stirred using a magnetic stirrer for up to 3 h at 25 ± 2 ºC. The samples were withdrawn and analyzed immediately at room temperature as per protocol (after 1, 2, and 3 h) and the data was compared with the initial values. The analytical data indicate that the chemical parameters of SCFE-50 C remained within the specification during the stirring period. The variation of the capsanthin content was found to be within the specified limit. The product is stable physically and chemically throughout the study.

UV spectrophotometer: make-Shimadzu, Japan. Model-1900i. Instrument conditions: multiple wavelength scanning mode (190–800 nm).

### Table 3
Stability of capsanthin content in the sample of saponified Capsicum annum fruit extract with capsanthin 50% w/w (SCFE-50 C) in corn oil after magnetic stirring up to 3 h under the experimental temperature of 25 ± 2 ºC using the HPLC analysis.

| Parameter Description | Specification |
|-----------------------|---------------|
| Identification        | To comply by UV |
| Loss on drying        | 1.28%          |
| Capsanthin            | 51.89%         |
| Total carotenoids     | 92.86%         |
reverse osmosis water were provided.

2.4. Vehicle and test item administration and observation

For vehicle control (G1) and vehicle control recovery (G1R) corn oil was used as such. Test item SCFE-50 C suspended at concentrations of...
Table 4
Summary of the male and female Sprague-Dawley rats hematological parameters after 90 days of oral repeated dose of SCFE-50 C.

| Parameter     | Males                       |                   | Females                       |                   |
|---------------|-----------------------------|-------------------|-------------------------------|-------------------|
|               | Control                     | SCFE-50 C (mg/kg BW/day) | Control                     | SCFE-50 C (mg/kg BW/day) |
|               | 500                         | 1000              | 2000                          | 500               | 1000              | 2000                          |
| WBC (10⁵ cells/mm³) | 8.46 ± 2.67                 | 8.86 ± 1.85       | 11.11 ± 2.79                  | 10.16 ± 2.67      | 11.61 ± 1.62      | 9.40 ± 2.85                  | 10.09 ± 2.37      | 6.80 ± 3.36 |
| RBC (10⁶ cells/mm³) | 8.65 ± 0.78                 | 9.29 ± 0.86       | 9.16 ± 0.98                   | 8.65 ± 0.38       | 8.05 ± 0.42       | 7.77 ± 0.25                  | 7.91 ± 0.64       | 7.63 ± 0.60 |
| HGB (g/dl)    | 15.01 ± 1.16                | 15.81 ± 1.43      | 16.06 ± 1.41                  | 14.98 ± 0.79      | 15.19 ± 0.62      | 14.71 ± 0.45                  | 14.94 ± 0.72      | 14.45 ± 0.99 |
| HCT (%)       | 46.02 ± 3.80                | 48.65 ± 4.69      | 49.23 ± 4.94                  | 45.82 ± 2.54      | 45.17 ± 1.67      | 43.23 ± 1.19                  | 44.13 ± 2.65      | 42.46 ± 3.41 |
| PLT (10⁶ cells/mm³) | 745.90                     | 829.20            | 706.45                        | 802.20            | 594.10            | 722.20 *                      | 718.90 *          | 773.60 *    |
| MCV (μm³)     | ± 302.42                    | ± 193.46          | ± 149.22                      | ± 90.78           | ± 116.87          | ± 93.95                      | ± 132.17          | ± 123.25    |
| MCH (pg)      | 53.40 ± 1.17                | 52.40 ± 1.26      | 53.80 ± 1.10                  | 53.10 ± 1.79      | 56.30 ± 1.89      | 55.60 ± 1.51                  | 55.90 ± 2.13      | 55.80 ± 1.14 |
| MCHC (g/dl)   | 73.60 ± 4.27                | 70.10 ± 2.60      | 70.70 ± 2.50                  | 71.90 ± 2.28      | 71.80 ± 2.30      | 71.60 ± 2.37                  | 72.00 ± 4.24      | 72.00 ± 4.47 |
| EOS (%)       | 1.00 ± 0.67                 | 1.80 * ± 0.63     | 2.10 * ± 0.57                 | 1.60 ± 0.70       | 1.30 ± 0.48       | 1.70 * ± 0.23                  | 1.40 ± 0.52       | 1.70 ± 0.48  |
| MON (%)       | 1.30 ± 0.82                 | 1.30 ± 0.48       | 1.30 ± 0.48                   | 1.40 ± 0.52       | 1.40 ± 0.70       | 1.50 ± 0.53                  | 1.40 ± 0.52       | 1.70 ± 0.48  |
| BAS (%)       | 0.00 ± 0.00                 | 0.00 ± 0.00       | 0.00 ± 0.00                   | 0.00 ± 0.00       | 0.00 ± 0.00       | 0.00 ± 0.00                  | 0.00 ± 0.00       | 0.00 ± 0.00  |
| RETIC (%)     | 3.24 ± 0.33                 | 3.14 ± 0.25       | 3.02 ± 0.48                   | 3.05 ± 0.26       | 3.01 ± 0.71       | 2.93 ± 0.30                  | 3.28 ± 0.36       | 2.62 ± 0.67  |
| PT (second)   | 13.55 ± 2.60                | 14.86 ± 2.58      | 17.46 ± 7.35                  | 11.68 ± 1.83      | 13.52 ± 4.15      | 11.93 ± 1.17                  | 13.71 ± 3.51      | 13.59 ± 2.55 |
| APTT (second) | 37.41 ± 4.65                | 39.12 ± 3.62      | 35.70 ± 5.07                  | 34.97 ± 6.54      | 39.18 ± 7.77      | 35.05 ± 5.22                  | 36.29 ± 6.00      | 37.15 ± 6.89 |

N = 10. Values are in Mean ± SD *Significantly different from Control group (P < 0.05, Student’s t test).

Table 5
Summary of the recovery male and female Sprague-Dawley rats hematological parameters after 90 days of oral repeated dose of SCFE-50 C.

| Parameter     | Recovery males |                   | Recovery females |                   |
|---------------|----------------|-------------------|------------------|-------------------|
|               | SCFE-50 C (mg/kg BW/day) |                   | SCFE-50 C (mg/kg BW/day) |                   |
|               | 500            | 1000              | 2000             | 500               | 1000              | 2000              |
| WBC (10⁵ cells/mm³) | 12.88          | 13.56             | 8.98 ± 1.10      | 9.68 ± 3.32      |
| RBC (10⁶ cells/mm³) | 8.99 ± 0.65    | 8.51 ± 0.52       | 8.02 ± 0.50      | 7.82 ± 0.31      |
| HGB (g/dl)    | 5.80 ± 0.65    | 15.40             | 15.58            | 14.86 ± 0.60     |
| HCT (%)       | 47.38          | 45.68             | 45.62            | 43.10 ± 1.96     |
| PLT (10⁶ cells/mm³) | 638.20         | 724.00            | 687.40           | 565.60           |
| MCV (μm³)     | ± 21.5 ± 2.58  | 612.88 ± 140.95   | 152.76           | 125.27           |
| MCH (pg)      | ± 17 ± 18.14   | 157.28 ± 53.80    | 56.60 ± 2.45     | 55.00 ± 2.45     |
| MCHC (g/dl)   | ± 17.84 ± 14.89 | ± 18.46           | 19.46 ± 0.94     | 19.04 ± 0.98     |
| NEU (%)       | 27 ± 2         | 26 ± 2            | 25 ± 4           | 24 ± 3           |
| LYM (%)       | 69 ± 1         | 72 ± 3            | 73 ± 4           | 73 ± 1           |
| EOS (%)       | 2 ± 1          | 1 ± 1             | 1 ± 1            | 1 ± 1            |
| MON (%)       | 2 ± 1          | 1 ± 1             | 1 ± 1            | 1 ± 1            |
| BAS (%)       | 0.0 ± 0.0      | 0.0 ± 0.0         | 0 ± 0            | 0 ± 0            |
| RETIC (%)     | 2.6 ± 0.4      | 2.8 ± 0.2         | 2.6 ± 0.3        | 3.0 ± 0.2        |
| PT (second)   | 14.19 ± 0.57   | 10.02 * ± 14.16   | 14.10            | 14.16 ± 1.70     |
| APTT (second) | 30.59 ± 0.80   | 29.52 * ± 3.59    | 31.08            | 30.93 ± 0.66     |

N = 5. Values are in Mean ± SD *Significantly different from Control group (P < 0.05, Student’s t test).

2.5. Ocular examination

Ocular examination was carried out for all rats on both eyes before start of treatment. At the end of the 90 days treatment period, the vehicle control and high dose group rat’s eyes were examined by a trained clinical veterinarian with an Ophthalmoscope. By using Tropicamide 1% solution, dilation was induced before the examination.
## 2.6. Feed consumption and Bodyweight gain

During the study period, the body weight was recorded once a week and at the end of the study period on the day of euthanasia before fasting. On weekly basis, feed consumption was measured during the dosing as well as the recovery period.

## 2.7. Urinalysis

Fresh urine was collected from all animals in a fasting state at the end of the study period and stored at 4°C. Combust10 Test strips (Roche Diagnost GmbH, Mannheim, Germany) used to measure Glucose, pH, and protein. Cobs u 411 urine analyzer instrument (Roche Diagnostics, Indianapolis, USA) was used to analyze urine chemistry parameters. The appearance and sedimentation were tested by visual inspection. Gravity meter (VET 360 Reichert Technologies, New York, USA) was used to check the specific gravity.

## 2.8. Hematology and blood chemistry

In this study, the hematology and blood chemistry parameters were selected based on the rat study reported by Tahir H et al. [18]. All the animals were kept in a biologic caging and blood samples were collected in the early morning between 7:00 and 9:00AM to reduce biological variation caused by circadian rhythms from all animals at the end of the experiment period under fasting conditions at least for 14 h but allowed access to water ad libitum. Under iso-flurane anesthesia, blood was collected from the retro-orbital plexus [19]. Blood samples were collected for clinical biochemistry, hematology, and coagulation parameters. Blood samples for hematology analysis were collected in tubes previously filled with 10% K2-EDTA (dipotassium ethylene diamine tetra acetic acid) solution. For coagulation parameters, blood samples were collected in tubes previously filled with 3.2% sodium citrate. Plain tubes were used to collect the blood samples for clinical chemistry and centrifuged to collect the serum. For the estimation of total serum T4, T3, and TSH levels for all animals, additional blood samples were collected, centrifuged and the serum stored at −70°C. The hematological parameters [20] such as mean corpuscular haemoglobin (MCH), mean corpuscular volume (MCV), mean corpuscular haemoglobin concentration (MCHC), haematocrit (HCT), platelet count (PC), partial thromboplastin time (PT), activated partial thromboplastin time (APTT), total leukocyte count (WBC), hemoglobin (HGB), erythrocyte count (RBC) and reticulocytes (RETIC), were analyzed using Hematology Analyzer (ABX Micros ESV 60, Horiba UK Limited, Northampton, UK) which was calibrated by using calibration standard Minocal calibrator.

Giemsa stain was used to enumerate the cells and blood smear was prepared by using typical techniques and the cell count was expressed as percentage. Blood smear examination was conducted by using the differential count method and basophils (BAS), lymphocytes (LYM), neutrophils (NEU), monocytes (MOM) and eosinophils (EOS) were recorded. Clinical chemistry parameters such as glucose (GLU), total protein (TP), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, ALB: Albumin, GGT: Gamma Glutamyl Transpeptidase, CA: Calcium, PHO: Phosphate, GLOB: Globulin, TBA: Total bile acids, ALP: Alkaline phosphatase, TBL: Total Bilirubin, BUN: Blood Urea Nitrogen, NA: Sodium, K: Potassium, CL: Chloride

## Table 6

Summary of the male and female Sprague-Dawley rats clinical chemistry parameters after 90 days of oral repeated dose of SCFE-50 C.

| Parameter       | Control (Males) | SCFE-50 C (mg/kg BW/day) | Control (Females) | SCFE-50 C (mg/kg BW/day) |
|-----------------|-----------------|----------------------------|-------------------|----------------------------|
| GLU (mg/dL)    | 83.59 ± 27.11   | 85.2 ± 27.57               | 94.19 ± 20.25     | 95.21 ± 17.22              |
| UREA (mg/dL)   | 27.32 ± 2.1     | 26.78 ± 2.14               | 29.73 ± 3.75      | 27.58 ± 3.36               |
| CRE (mg/dL)    | 0.59 ± 0.03     | 0.59 ± 0.02                | 0.63 ± 0.04       | 0.62 ± 0.04                |
| TCHO (mg/dL)   | 47.19 ± 5.64    | 51.33 ± 17.69              | 49.09 ± 10.2      | 50.29 ± 9.09               |
| TRIG (mg/dL)   | 49.39 ± 15.12   | 41.22 ± 14.29              | 52.45 ± 18.56     | 56.47 ± 20.47              |
| AST (U/L)      | 115.21 ± 33.46  | 125.28 ± 36.15             | 121.09 ± 31.58    | 99.87 ± 15.63              |
| ALT (U/L)      | 40.07 ± 10.04   | 37.71 ± 7.73               | 43.67 ± 11.52     | 36.74 ± 5.27               |
| TP (g/L)       | 64.99 ± 1.9     | 65.79 ± 3.03               | 68.66 ± 3.38      | 65.33 ± 3.58               |
| HDL (mg/dL)    | 12.96 ± 1.91    | 15.98 ± 5.64               | 16.66 ± 3.66      | 17.31 ± 3.61               |
| LDL (mg/dL)    | 9.1 ± 2.02      | 11.26 ± 6.6                | 11.95 ± 2.33      | 10.85 ± 4.34               |
| ALB (g/L)      | 34.27 ± 8.4     | 34.63 ± 7.15               | 41.78 ± 11.3      | 31.57 ± 10.99              |
| GGT (U/L)      | 0.4 ± 0.94      | 0.8 ± 1.33                 | 0.22 ± 0.71       | 0.05 ± 0.16                |
| CA (mmol/L)    | 2.69 ± 0.7      | 2.41 ± 0.34                | 2.2 ± 0.2         | 2.33 ± 0.55                |
| PHO (mg/dL)    | 7.68 ± 0.89     | 7.7 ± 1.01                 | 8.4 ± 1.95        | 8.04 ± 1.45                |
| GLOB (g/L)     | 32.07 ± 7.05    | 28.67 ± 10.25              | 26.89 ± 13.72     | 33.76 ± 12.14              |
| TBA (umol/L)   | 25.23 ± 23.34   | 32.81 ± 34                 | 12.53 ± 6.01      | 11.14 ± 5.5                |
| ALP (U/L)      | 89.06 ± 31.06   | 69.45 ± 13.37              | 88.76 ± 41.9      | 117.64 ± 36.97             |
| TRB (U/L)      | 0.31 ± 0.04     | 0.31 ± 0.17                | 0.29 ± 0.07       | 0.31 ± 0.05                |
| BUN (mg/dL)    | 12.77 ± 0.98    | 12.51 ± 1.1                | 13.89 ± 1.75      | 12.89 ± 1.59               |
| NA (mmol/L)    | 143.2 ± 1.23    | 143 ± 1.63                 | 143.8 ± 1.55      | 143.3 ± 1.7                |
| K (mmol/L)     | 5.68 ± 0.63     | 5.58 ± 0.84                | 5.43 ± 0.58       | 5.11 ± 0.54                |
| CL (mmol/L)    | 10.4 ± 1.43     | 10.48 ± 1.55               | 10.53 ± 1.06      | 10.46 ± 1.51               |

N = 10. Values are in Mean ± SD *Significantly different vs Control group (P < 0.05, Student’s t-test).

GLU: Glucose, CRE: Creatinine, TCHO: Total Cholesterol, TRIG: Triglycerides, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, TP: Total protein, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, ALB: Albumin, GGT: Gamma Glutamyl Transpeptidase, CA: Calcium, PHO: Phosphate, GLOB: Globulin, TBA: Total bile acids, ALP: Alkaline phosphatase, TBL: Total Bilirubin, BUN: Blood Urea Nitrogen, NA: Sodium, K: Potassium, CL: Chloride

2.9. 2.9 Serum hormone analysis

Serum levels of thyroid hormones (THs) L-thyroxine (T4), L-triiodothyronine (T3) as well as thyroid-stimulating hormone (TSH) in control and treated groups were quantified. Concentrations of thyroid hormones in serum samples were analyzed by using enzyme-linked immunosorbent assay (ELISA) kits. T3 was calculated using a rat ELISA test kit (Cat No. K11–0535, Lot No. RT03702, KinesisDx, Brea, USA) and expressed in pg/ml, whilst T4 was calculated using a rat ELISA test kit (Cat No. K11–0338, Lot No. RT40720, KinesisDx, Brea, USA).
Table 7
Summary of the recovery male and female Sprague-Dawley rats clinical chemistry parameters after 90 days of oral repeated dose of SCFE-50 C.

|                         | Recovery males                          | Recovery females                         |
|-------------------------|-----------------------------------------|------------------------------------------|
|                         | Control SCFE-50 C (mg/kg BW/day) 2000   | Control SCFE-50 C (mg/kg BW/day) 2000    |
| GLU (mg/dL)             | 103.62 ± 16.02                         | 101.11 ± 29.16                           |
|                         | 96.06 ± 20.72                          | 100.54 ± 26.9                            |
| UREA (mg/dL)            | 34.59 ± 4.16                           | 31.15 ± 15.36                            |
|                         | 33.27 ± 4.09                           | 31.36 ± 8.26                             |
| CRE (mg/dL)             | 0.77 ± 0.02                            | 0.67 ± 0.24                              |
|                         | 0.71 ± 0.03                            | 0.76 ± 0.2                               |
| TRIG (mg/dL)            | 49.33 ± 7.6                            | 54.71 ± 20.85                            |
|                         | 48.66 ± 11.22                          | 60.36 ± 19.19                            |
| TBA (U/L)               | 56.97 ± 25.32                          | 51.64 ± 23.17                            |
|                         | 51.67 ± 14.16                          | 52.67 ± 20.41                            |
| PHO (mg/dL)             | 68.76 ± 7.86                           | 65.38 ± 40.86                            |
|                         | 76.71 ± 1.18                           | 44.34 ± 17.15                            |
| HDL (mg/dL)             | 15.67 ± 0.66                           | 10.65 ± 6.68                             |
|                         | 14.28 ± 2.5                            | 23.25 ± 9.07                             |
| LDL (mg/dL)             | 12.94 ± 3.55                           | 19.17 ± 9.17                             |
|                         | 12.48 ± 5.31                           | 23.25 ± 9.07                             |
| ALB (g/L)               | 24.66 ± 8.92                           | 24.93 ± 10.06                            |
|                         | 21.51 ± 6.28                           | 22.94 ± 8.51                             |
| GGT (U/L)               | -1.31 ± 1.3                            | -1.83 ± 0.24                             |
|                         | -4.24 ± 3.42                           | -0.24 ± 2.67                             |
| CA (mmol/L)             | 3.26 ± 0.39                            | 2.21 ± 0.86                              |
|                         | 2.98 ± 0.51                            | 2.52 ± 0.9                               |
| PHO (mg/dL)             | 9.22 ± 1.38                            | 5.43 ± 2.65                              |
|                         | 9.59 ± 4.13                            | 4.55 ± 2.14                              |
| GLOB (g/L)              | 44.1 ± 8.11                            | 44.12 ± 14.87                            |
|                         | 46.2 ± 6.16                            | 45.88 ± 14.27                            |
| TBA (µmol/L)            | 22.75 ± 11.8                           | 42.28 ± 40.8                             |
|                         | 24.77 ± 7.82                           | 49.08 ± 40.4                             |
| ALP (U/L)               | 63.09 ± 26.71                          | 46.78 ± 25.4                             |
|                         | 56.38 ± 14.29                          | 35.65 ± 24.3                             |
| PHO (mg/dL)             | 0.08 ± 0.12                            | 0.1 ± 0.06                               |
|                         | 0.07 ± 0.06                            | 0.01 ± 0.07                              |
| TBA (µmol/L)            | 14.42 ± 2.59                           | 14.45 ± 3.86                             |
|                         | 144.2 ± 25.9                           | 14.65 ± 3.86                             |
| BUN (mg/dL)             | 4.94 ± 0.36                            | 4.3 ± 1.47                               |
|                         | 4.8 ± 0.2                              | 4.23 ± 1.09                              |
| ALP (µmol/L)            | 104.6 ± 1.52                           | 95.27 ± 22.88                            |
|                         | 103.00 ± 0.71                          | 95.71 ± 22.28                            |

N = 5. Values are in Mean ± SD *Significantly different vs Control group (P < 0.05, Student’s t test).

GLU: Glucose, CRE: Creatinine, TCHO: Total Cholesterol, TRIG: Triglycerides, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, TP: Total protein, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, ALB: Albumin, GGT: Gamma Glutamyl Transpeptidase, CA: Calcium, PHO: Phosphate, GLOB: Globulin, TBA: Total bile acids, ALP: Alkaline phosphatase, TBL: Total Bilirubin, BUN: Blood Urea Nitrogen, NA: Sodium, K: Potassium, CL: Chloride

USA) and expressed in ng/mL. TSH was measured in IU/mL using a rat ELISA test kit (Cat No. K11-0181, Lot No. TSH0720, KinesixDx, Brea, USA).

2.10. Necropsy and histopathology

All rats were euthanized by CO2 asphyxiation followed by exsanguination. Rats were exposed to 20–30% CO2 in the euthanasia chamber until visible movements have ceased. The non-responsiveness of the animals was confirmed by the paw pinch reflex method. The animals were exsanguinated by severing the inferior vena cava after performing chest thoracotomy. A complete macroscopic postmortem examination [22] was performed on all rats, including the external surfaces of the carcass, all orifices, the cranial, thoracic, and abdominal cavities. The visible abnormalities were recorded. Organs such as heart, spleen, liver, brain, thymus, adrenal, kidney, epididymis or uterus, testes or ovaries, Prostate + seminal vesicles with coagulating glands, Thyroid gland (after fixation), and Pituitary gland (after fixation) were weighed and recorded. Organs and tissues were harvested and preserved in 10% neutral buffered formalin for necropsy analysis.

Organs and tissues such as the aorta, axillary/neck lymph node, adrenal glands, brain (cerebrum, cerebellum, medulla/pons), bone and bone marrow (femur), mesenteric lymph nodes, nerve, sciatic, spinal cord (cervical, thoracic and lumbar), skeletal muscle, skin (with mammary gland for male and female), cecum, epididymis, esophagus, trachea, rectum, prostate + seminal vesicles with coagulating glands, salivary glands, spleen, stomach, thyroid with parathyroids, thymus, duodenum, heart, colon gross lesions, ileum with Peyers Patch, jejunum, kidneys, liver, lungs, ovaries, pancreas, pituitary gland, uterus with cervix vagina and urinary bladder. The eyes including the optic nerve and tests were harvested and stored in 10% neutral buffered formalin before that they were fixed in Davidson’s fixative.

For histopathological evaluation [22], specimens of the preserved tissues were embedded in paraffin and before that, they were trimmed and dehydrated. The paraffin-embedded tissues were stained with Mayer’s hematoxylin-eosin staining kit. A preserving medium 10% neutral buffered formalin was used to store all residual organs.

2.10.1. Histopathology grading schemes

In histopathologic diagnosis, the severity grades are important and provide vital information about the treatment-related toxicity in the preclinical studies. The interstitial thickening and peribronchial inflammation were graded in parallel where 0 indicated no injury, grade 1 (minimal) indicated injury to 25% of the field, grade 2 (mild) indicated injury to 50% of the field, grade 3 (moderate) indicated injury to 75% of the field, and grade 4 (severe) indicated diffuse injury [23].

The severity of Hepatocellular necrosis graded as grade 0: within normal limits, grade 1 (minimal): approximately < 5% of centrilobular hepatocytes are necrotic, grade 2 (mild): approximately 5–20% of the liver is affected by centrilobular hepatocyte necrosis that is often circumferential, grade 3 (moderate): approximately 20–40% of the liver is affected by centrilobular hepatocyte necrosis that is often circumferential and bridging, grade 4 (marked): generally > 50% of the liver is affected by centrilobular necrosis that is bridging, confluent, and often extends beyond centrilobular zones [24].

Renal lesions in treated animals were assessed and graded into five categories by utilizing a scale of 0–5 [25]. Grade 0: normal histology, Grade 1 (minimal): tubular epithelial cell degeneration, without significant necrosis/apoptosis, grade 2 (mild): < 25%, grade 3 (moderate): < 50%, grade 4 (marked): < 75%, grade 5 (extreme): > 75% of the tubules showing tubular epithelial cell necrosis/apoptosis, respectively, accompanied by other concomitant alterations.

2.11. Analysis of capsathin levels in macula and plasma

Eye and plasma were collected from the rats treated with SCFE-50 C for 90 days at different dose levels (G2, G3, and G4) and vehicle control (G1). Plasma from three rats from each groups was collected and mixed. Post sacrifice, the eye was collected, and the macula portion was excised. In each treatment group, macula from three rats was pooled and the homogenate was prepared using 500 µL of Phosphate buffered saline in presence of sterile metal beads. The homogenate was centrifuged (10000 rpm, 10 min at 4°C) and the supernatant was flash-frozen using liquid nitrogen. Samples were stored in − 80°C deep freezer until LCMS/MS analysis. Ethyl acetate 2 mL was added to 50 µL plasma or macula supernatant and vortexed for 10 min and clarified by centrifugation at
Table 8  
Summary of the male and female Sprague-Dawley rats thyroid hormone estimation after 90 days of oral repeated dose of SCFE-50 C.

| Parameter | Control SCFE-50 C (mg/kg BW/day) | Control SCFE-50 C (mg/kg BW/day) |
|-----------|---------------------------------|---------------------------------|
|           | 500                             | 1000                            | 2000                             |
| T3 (pg/mL)| 571.019 ± 5.385                 | 602.909 ± 5.456                 | 504.881 ± 5.385                  |
| T4 (ng/mL)| 25.317 ± 2.977                  | 25.371 ± 2.133                  | 26.083 ± 2.029                  |
| TSH (µIU/| 1.3165 ± 0.3498                  | 1.3411 ± 0.2587                 | 1.3999 ± 0.2161                 |

N = 5. Values are in Mean ± SD *Significantly difference vs Control group (P < 0.05, Student’s t test).

2.12. Statistical analysis

Graphpad Prism V7.04 [26] was used to perform Statistical analysis. Data on body weight, feed consumption, organ weights as well as clinical pathology data against the respective vehicle control group. Data normality was performed using Shapiro-Wilk test. Data for each group of animals were subjected to analysis of variance (ANOVA). T-test was used to compare the difference between control and treated recovery groups. Values were given as mean ± standard deviation (SD). All comparisons and analyses were evaluated at a 5% significance (P ≤ 0.05) level.

3. Results

3.1. Quantification of capsanthin

Capsanthin was estimated in the Capsanthin SCFE-50 C according to the method described in Paprika extract, FAO JECFA monograph. Fig. 1 show HPLC chromatograms of capsanthin standard and SCFE-50 C. As shown in Fig. 1, the retardation time of capsanthin in the standard solution was identical with capsanthin in the SCFE-50 C. A high abundance of capsanthin was eluted and resulting in capsanthin being the only major component present in capsanthin enriched extract. The content of capsanthin in SCFE-50 C was 50.59% (w/w) and the total carotenoids was 92.86% (w/w).

3.2. Stability of SCFE-50 C

The physical and chemical stability of SCFE-50 C was evaluated as per international conference on Harmonization guidelines. Test samples of SCFE-50 C was stored at 5º ± 3ºC for one year. The samples were packaged in Low density polyethylene bags and purged with nitrogen. Evaluations for physical and chemical stability were performed initially, after 3-, 6-, 9- and 12-months storage periods. Physical stability was assessed by organoleptic. The chemical stability of the SCFE-50 C was

Table 9  
Summary of the recovery male and female Sprague-Dawley rats thyroid hormone estimation after 90 days of oral repeated dose of SCFE-50 C.

| Parameter | Control SCFE-50 C (mg/kg BW/ day) | Control SCFE-50 C (mg/kg BW/ day) |
|-----------|---------------------------------|---------------------------------|
|           | 2000                            | 2000                            |
| T3 (pg/mL)| 557.039 ± 81.5049               | 585.5482 ± 60.4928              |
| T4 (ng/mL)| 28.4203 ± 2.7335                | 25.1431 ± 0.7258                |
| TSH (µIU/| 1.9025 ± 0.4468                 | 1.2336 ± 0.2487                 |
| ml       | 581.8629 ± 39.2861              | 24.3641 ± 1.8479                |

N = 5. Values are in Mean ± SD *Significantly difference vs Control group (P < 0.05, Student’s t test).

Table 10  
Summary of the male and female Sprague-Dawley rats urinalysis parameters after 90 days of oral repeated dose of SCFE-50 C.

| Parameter | Control SCFE-50 C (mg/kg BW/day) | Control SCFE-50 C (mg/kg BW/day) |
|-----------|---------------------------------|---------------------------------|
|           | 500                             | 1000                            | 2000                             |
| APP       | 0/10                            | 0/10                            | 0/10                             |
| VOL (ml)  | 16 ± 8                          | 13 ± 4                          | 12 ± 4                           |
| SPG       | 1.019 ± 0.006                   | 1.02 ± 0.005                    | 1.018 ± 0.005                    |
| pH        | 8.8 ± 0.4                       | 8.8 ± 0.4                       | 8.7 ± 0.5                        |
| WBC (No/| 1/10                            | 0/10                            | 0/10                             |
| ml/µL     | 1/10                            | 1/10                            | 1/10                             |
| GLU (mg/| 0/10                            | 0/10                            | 0/10                             |
| ml        | 0/10                            | 0/10                            | 0/10                             |
| ERY (No/| 0/10                            | 0/10                            | 0/10                             |

N = 10. Values are in Mean ± SD. No significant difference between treated and Control group (Student’s t test).

APP: Appearance, VOL: Volume, SPG: Specific gravity, WBC: Total leukocyte count, PRO: Protein, GLU: Glucose, ERY: Erythrocytes
The hematology analyzer was calibrated and found the results are agreeable with the calibration standard. Toxicologically significant changes were not observed in all hematological parameters in any groups and well within the historical control data.

In males, a statistically significant increase in eosinophil count was observed in G2 (1.8%) and in G3 (2.1%) when compared with the vehicle control group (1.0%). Females showed statistically significant decrease in WBC count in G4 (6.80 × 10³ cells/mm³) (G1 = 11.61 × 10³ cells/mm³) and increase in level of platelet in G2 (722.20 × 10³ cells/mm³), G3 (718.90 × 10³ cells/mm³) and G4 (773.60 × 10³ cells/mm³) groups in comparison to the vehicle control group (594.10 × 10³ cells/mm³). However, the changes in the eosinophil count and platelet count in the main group were considered as treatment related but reversible after the treatment stopped.

In recovery males lymphocyte percentage (72%) (G1R = 69%) was increased significantly. Coagulation parameters i.e., PT (15.02 s) (G1R = 14.19) was increased whereas, APTT (29.52 s) (G1R = 30.59) was decreased significantly when compared with the respective recovery control group. In recovery females, reticulocytes (3.0%) (G1R = 2.6%) and PT (14.16 s) (G1R = 14.10 s) were increased significantly in comparison to the recovery vehicle control group. In these parameters no corresponding changes were observed in the high dose group at the end of the treatment period. So, the changes observed were considered as incidental and toxicologically not relevant. The hematology parameters for male and female rats in all groups are shown in Table 4 and for recovery male and female groups are shown in Table 5.

### 3.5. Hematology

The oxidative stability study of SCFE-50 C in corn oil revealed that Capsanthin was stable up to 3 h. No physical changes were observed in 5%, 10% and 20% of SCFE-50 C in corn oil throughout the study. The Capsanthin content was found to be within the specified limit for all the withdrawals and stable for 3 h at room temperature. The data are presented as Table 2.

### 3.3. Oxidative stability of capsanthin

The oxidative stability study of SCFE-50 C in corn oil revealed that Capsanthin was stable up to 3 h. No physical changes were observed in 5%, 10% and 20% of SCFE-50 C in corn oil throughout the study. The Capsanthin content was found to be within the specified limit for all the withdrawals and stable for 3 h at room temperature. The data are presented as Table 3.

### 3.4. Clinical observation, body weight and feed consumption

No mortality, abnormalities of body weight changes or food consumption were observed in the treated group in both sexes when compared to the respective control group. Statistically significant lower body weight gain during days 29–36 in G2 males (G1 = 22.49 g; G2 = 5.98 g) and statistically significant higher body weight gain during days 36–43 in G3 males (G1 = 8.18 g; G3 = 27.98 g) and lower body weight gain during days 29–36 in G2 females were observed (G1 = 9.65 g; G2 = 0.74 g). Statistically significant higher body weight gain during Days 1–8 (G1R = 18.79 g; G4R = 31.09 g), 29–36 (G1R = 3.28 g; G4R = 14.74 g) and 57–64 (G1R = 1.74 g; G4R = 4.27 g) in females of G4R group. The weekly percentage mean body weight gain of the vehicle control and treated groups on week six was lower and over the course of the experiment was within the acceptable range. The percentage mean body weight change for main male and recovery group is given in Fig. 2. For female main and recovery groups are given in Fig. 3. Feed consumption was monitored from the first week for all groups G1 to G4 till the end of thirteen weeks (90 days) and was found to be comparable across all the test groups and the data are shown in Fig. 4A & 4B.

These changes in body weight gain were not dependent on the dose. Hence, these findings were considered incidental in nature. No treatment-related variation in the mean body weights and net body weight gains in any of the groups in both sexes when compared to the respective vehicle controls.

### 3.6. Clinical chemistry

The clinical chemistry analyzer was calibrated before performing the analysis and found the results are well within the calibration standard specification. The Quality control report for clinical chemistry analyzer is shown in Table 7. In all clinical chemistry parameters, toxicologically significant changes were not observed in all groups and complies with the historical control data. In males, a statistically significant increase in the level of creatinine was observed in G3 (0.63 mg/dL) in comparison with the vehicle control group (0.59 mg/dL). In females, the glucose level was increased statistically in G2 (87.00 mg/dL) and G4 (94.93 mg/dL) compared to control group (0.59 mg/dL). In females, the glucose level was increased statistically in G2 (87.00 mg/dL) and G4 (94.93 mg/dL) compared to control group (0.59 mg/dL). However, no corresponding changes were observed at the end of the recovery period. In recovery males, statistically significant decrease in level of GGT (−4.24 U/L) (G1R = −1.31 U/L), creatinine (0.71 mg/dL) (G1R = 0.77 mg/dL) and chloride (103.00 mmol/L) (G1R = 104.60 mmol/L) was observed when compared with the recovery vehicle control group. In female recovery group, total protein (68.46 g/ L) (G1R = 67.52), globulin (45.88 g/L) (G1R = 44.42), sodium (132.42 mmol/L) (G1R = 130.82) and chloride (95.71 mmol/L) (G1R = 95.27 mmol/L) level was increased. Whereas only Albumin (22.94 g/L) (G1R = 24.93) level was decreased in comparison to the respective control group. These treatment related minor changes observed in clinical chemistry parameters were not consistent in main and recovery groups and observed in only one of the sexes but reversed after treatment stopped. The summarized values of clinical parameters for male and female rats are shown in Table 6 and for recovery male and female groups are shown in Table 7.
### Table 12
Summary of the male and female Sprague-Dawley rats body weight, absolute and relative organ weights after 90 days of oral repeated dose of SCFE-50 C.

|                     | Males SCFE-50 C (mg/kg BW/day) | Females SCFE-50 C (mg/kg BW/day) |
|---------------------|-------------------------------|---------------------------------|
|                     | Control 500 | 1000 | 2000 | Control 500 | 1000 | 2000 |
| Body weight         | 517.86 ± 48.13 | 511.4 ± 49.20 | 518.58 ± 59.47 | 293.36 ± 22.27 | 285.88 ± 23.73 | 299.44 ± 26.71 |
| Liver               | 13.51 ± 2.27 | 12.62 ± 1.71 | 13.63 ± 3.76 | 8.52 ± 0.85 | 8.2 ± 1.11 | 7.9 ± 0.87 |
| Kidneys             | 3.21 ± 0.33 | 2.89 ± 0.36 | 3.2 ± 0.59 | 1.86 ± 0.22 | 1.75 ± 0.20 | 1.78 ± 0.20 |
| Adrenals            | 0.07 ± 0.02 | 0.07 ± 0.01 | 0.06 ± 0.02 | 0.07 ± 0.01 | 0.07 ± 0.02 | 0.08 ± 0.01 |
| Spleen              | 0.8 ± 0.10 | 0.73 ± 0.14 | 0.79 ± 0.19 | 0.53 ± 0.10 | 0.47 ± 0.08 | 0.55 ± 0.08 |
| Heart               | 1.79 ± 0.29 | 1.65 ± 0.30 | 1.71 ± 0.30 | 1.06 ± 0.14 | 0.99 ± 0.07 | 1.09 ± 0.12 |
| Thymus              | 0.39 ± 0.10 | 0.41 ± 0.12 | 0.42 ± 0.17 | 0.38 ± 0.09 | 0.31 ± 0.09 | 0.36 ± 0.09 |
| Brain               | 2.23 ± 0.16 | 2.23 ± 0.12 | 2.13 ± 0.17 | 2.04 ± 0.06 | 2 ± 0.13 | 2.04 ± 0.14 |
| Thyroid / Parathyroid gland | 0.18 ± 0.01 | 0.16 ± 0.00 | 0.18 ± 0.00 | 0.17 ± 0.01 | 0.17 ± 0.01 | 0.17 ± 0.00 |
| Pituitary gland     | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 | 0.02 ± 0.00 |
| Prostate + seminal vesicles with coagulating glands | 2.5 ± 0.67 | 2.78 ± 0.95 | 2.94 ± 0.93 | – | – | – |
| Testes              | 3.74 ± 0.22 | 3 ± 0.29 | 3.65 ± 0.35 | – | – | – |
| Epididymis          | 1.55 ± 0.11 | 1.63 ± 0.15 | 1.74 ± 0.45 | 0.2 ± 0.06 | 0.19 ± 0.03 | 0.2 ± 0.05 |
| Ovaries             | – | – | – | 0.76 ± 0.05 | 0.75 ± 0.14 | 0.73 ± 0.20 |
| Uterus              | – | – | – | 0.82 ± 0.25 | 0.82 ± 0.25 | 0.82 ± 0.25 |
| Relative organ weights |                     |                     |                     |                     |                     |                     |
| Liver               | 2.6 ± 0.28 | 2.4 ± 0.21 | 2.6 ± 0.50 | 1.65 ± 0.15 | 1.61 ± 0.22 | 1.53 ± 0.50 |
| Kidneys             | 0.62 ± 0.05 | 0.56 ± 0.04 | 0.61 ± 0.06 | 0.36 ± 0.04 | 0.34 ± 0.03 | 0.35 ± 0.06 |
| Adrenals            | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 |
| Spleen              | 0.15 ± 0.01 | 0.14 ± 0.03 | 0.15 ± 0.03 | 0.15 ± 0.01 | 0.1 ± 0.01 | 0.11 ± 0.03 |
| Heart               | 0.35 ± 0.04 | 0.32 ± 0.06 | 0.33 ± 0.05 | 0.33 ± 0.06 | 0.21 ± 0.02 | 0.21 ± 0.05 |
| Thymus              | 0.08 ± 0.02 | 0.08 ± 0.08 | 0.09 ± 0.08 | 0.21 ± 0.02 | 0.2 ± 0.02 | 0.2 ± 0.02 |
| Brain               | 0.43 ± 0.04 | 0.44 ± 0.01 | 0.41 ± 0.04 | 0.41 ± 0.07 | 0.39 ± 0.03 | 0.4 ± 0.04 |
| Thyroid / Parathyroid gland | 0.03 ± 0.00 | 0.03 ± 0.03 | 0.03 ± 0.04 | 0.03 ± 0.00 | 0.03 ± 0.00 | 0.03 ± 0.00 |
| Pituitary gland     | 0 ± 0.00 | 0.003 ± 0.001 | 0.004 ± 0.001 | 0.004 ± 0.001 | 0.003 ± 0.001 | 0.003 ± 0.001 |
| Prostate + seminal vesicles with coagulating glands | 0.48 ± 0.12 | 0.54 ± 0.18 | 0.56 ± 0.16 | 0.43 ± 0.10 | – | – |
| Testes              | 0.73 ± 0.10 | 0.71 ± 0.10 | 0.71 ± 0.08 | 0.67 ± 0.07 | – | – |
| Epididymis          | 0.3 ± 0.03 | 0.32 ± 0.05 | 0.33 ± 0.07 | 0.3 ± 0.07 | – | – |
| Ovaries             | – | – | – | 0.04 ± 0.01 | 0.04 ± 0.00 | 0.04 ± 0.07 |
| Uterus              | – | – | – | 0.15 ± 0.03 | 0.15 ± 0.04 | 0.16 ± 0.16 |

N = 10. Values are in Mean ± SD *Significantly difference vs Control group (P < 0.05, Student’s t test).

3.7. Serum thyroid hormone estimation

There were no SCFE-50 C related changes in the serum hormone levels in any of the group. In high dose female group (G4), there was a significant decrease in the level of T3 (505.1 pg/mL) and decreased TSH (1.2 µIU/mL) compared with vehicle control group G1 (T3 = 582.3 pg/dL, T4 = 1.4 µIU/mL) observed. However, no corresponding changes were observed during the histopathology examination. In recovery group male rats, a statistically significant decrease in the level of T4 (25.1 ng/mL) (G1R = 28.4 ng/mL) was observed and it was considered as incidental as no change in the level of TSH and T4 were observed and also no change in the level of T4 was observed at the end of the treatment period. The summarized values for male and female rats are shown in Table 8 and for recovery male and female rats are shown Table 9.

3.8. Urinalysis observation

There were no statistically significant changes in the urine volume in any Capsanthin treated groups and control groups except the recovery group. The urine output volume was found to be increased in both recovery male (14 mL) (G1R = 10 mL) and female group (15 mL) (G1R = 10 mL) in comparison to the control group animals. Besides, the
Table 13
Summary of the recovery male and female Sprague-Dawley rats body weight, absolute and relative organ weights after 90 days of oral repeated dose of SCFE-50 C.

| Tissue with lesion | Male Recovery SCFE-50 C (mg/kg BW/ day) | Male Recovery SCFE-50 C (mg/kg BW/day) | Female Recovery SCFE-50 C (mg/kg BW/ day) | Female Recovery SCFE-50 C (mg/kg BW/day) |
|--------------------|------------------------------------------|----------------------------------------|--------------------------------------------|------------------------------------------|
| Body weight        | 550.23 ± 589.32                          | 292.46 ± 285.78                        | 550.23 ± 589.32                            | 292.46 ± 285.78                          |
| Liver              | 14.73 ± 16.82 ± 0.06                      | 8.52 ± 9.15 ± 1.27                     | 14.73 ± 16.82 ± 0.06                       | 8.52 ± 9.15 ± 1.27                       |
| Kidneys            | 3.47 ± 3.62 ± 0.56                        | 1.84 ± 1.98 ± 0.12                     | 3.47 ± 3.62 ± 0.56                        | 1.84 ± 1.98 ± 0.12                       |
| Adrenals           | 0.06 ± 0.06 ± 0.01                        | 0.06 ± 0.06 ± 0.02                     | 0.06 ± 0.06 ± 0.01                        | 0.06 ± 0.06 ± 0.02                       |
| Spleen             | 0.75 ± 0.88 ± 0.25                        | 0.5 ± 0.47 ± 0.10                      | 0.75 ± 0.88 ± 0.25                        | 0.5 ± 0.47 ± 0.10                        |
| Heart              | 1.84 ± 1.75 ± 0.23                        | 1.02 ± 1.11 ± 0.07                     | 1.84 ± 1.75 ± 0.23                        | 1.02 ± 1.11 ± 0.07                       |
| Thymus             | 0.35 ± 0.44 ± 0.13                        | 0.26 ± 0.3 ± 0.06                      | 0.35 ± 0.44 ± 0.13                        | 0.26 ± 0.3 ± 0.06                       |
| Brain              | 2.08 ± 2.28 ± 0.13                        | 1.89 ± 1.9 ± 0.12                      | 2.08 ± 2.28 ± 0.13                        | 1.89 ± 1.9 ± 0.12                       |
| Thyroid / Parathyroid gland | 3.57 ± 3.54 ± 0.09 | 0.28 ± 0.33 ± 0.09                 | 3.57 ± 3.54 ± 0.09                        | 0.28 ± 0.33 ± 0.09                       |
| Pituitary gland    | 1.66 ± 1.72 ± 0.24                        | 0.02 ± 0.01 ± 0.00                     | 1.66 ± 1.72 ± 0.24                        | 0.02 ± 0.01 ± 0.00                       |
| Prostate + seminal vesicles with coagulating glands | 3.05 ± 2.86 ± 0.19 | – – – –                          | 3.05 ± 2.86 ± 0.19                        | – – – –                                |

Table 14
Summary of the male and female Sprague-Dawley rats histopathology observation after 90 days of oral repeated dose of SCFE-50 C.

| Tissue with lesion | Male Control SCFE-50 C (mg/kg BW/day) | Male Control SCFE-50 C (mg/kg BW/day) | Female Control SCFE-50 C (mg/kg BW/day) | Female Control SCFE-50 C (mg/kg BW/day) |
|--------------------|----------------------------------------|----------------------------------------|------------------------------------------|------------------------------------------|
| Adrenal glands     | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| Aorta              | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| Axillary/neck lymph node | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| Bone and bone marrow (femur) | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| Brain (cerebrum, cerebellum, medulla/pons) | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| Eyes (with optic nerve) | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| Heart              | 1/10                                   | 1/10                                   | 1/10                                     | 1/10                                     |
| Gastrointestinal tract | – –                                    | – –                                    | – –                                      | – –                                      |
| - Cecum            | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| - Colon            | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| - Duodenum         | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| - Epipylones       | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| - Esophagus        | 0/10                                   | 0/10                                   | 0/10                                     | 0/10                                     |
| - Ileum with Peyer’s Patch within normal limit | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| - Jejunum within normal limit | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| - Kidneys          | 4/10                                   | 5/10                                   | 3/10                                     | 3/10                                     |
| - Interstitial hemorrhage - minimal multifocal | 0/10                                  | 2/10                                   | 1/10                                     | 1/10                                     |
| - Intestinal hemorrhage - mild multifocal | 1/10                                  | 2/10                                   | 1/10                                     | 2/10                                     |
| - Tubulare degeneration - minimal multifocal | 1/10                                  | 1/10                                   | 2/10                                     | 1/10                                     |
| - Tubulare degeneration - mild diffuse | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| - Infiltration of inflammatory cell - minimal multifocal | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| - Liver            | 4/10                                   | 6/10                                   | 5/10                                     | 6/10                                     |
| - Infiltration of inflammatory cell - minimal multifocal | 0/10                                  | 1/10                                   | 0/10                                     | 1/10                                     |
| - Lungs            | 3/10                                   | 4/10                                   | 6/10                                     | 4/10                                     |
| - Sinusoidal congestion - mild diffuse | 2/10                                  | 2/10                                   | 2/10                                     | 2/10                                     |
| - Peribronchiolar cell infiltration - mild multifocal | 1/10                                  | 2/10                                   | 1/10                                     | 2/10                                     |
| Mesenteric lymph nodes | 0/10                                  | 0/10                                   | 0/10                                     | 0/10                                     |
| Skin (with mammary gland for male and female) | 10/10                                 | 10/10                                  | 10/10                                    | 10/10                                    |

N = 5. Values are in Mean ± SD *Significantly difference vs Control group (P < 0.05, Student’s t test).
The presence of capsanthin was confirmed using the particle size grade of 0 (no injury), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (extreme) gas flow: 800 L/hr., desolvation temperature: 450 ºC, source temperature: 120 ºC, capillary voltage: 2.5KV, Cone: 40 V, Cone gas flow: 50 L/hr. Isocratic mobile phase-

### Table 14 (continued)

| Tissue with lesion                      | Male Control SCFE-50 C (mg/kg BW/day) | Female Control SCFE-50 C (mg/kg BW/day) | Male SCFE-50 C (mg/kg BW/day) | Female SCFE-50 C (mg/kg BW/day) |
|----------------------------------------|--------------------------------------|----------------------------------------|------------------------------|----------------------------------|
|                                        | 0/0                                  | 0/0                                    | 0/0                          | 0/0                              |
| Nerve, sciatic                         | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Pituitary gland                         | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Salivary glands                         | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Spinal cord (cervical, thoracic and lumbar) | 10/10                                | 10/10                                  | 10/10                        | 10/10                            |
| Thymus                                  | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Thyroid with parathyroids               | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Trachea                                 | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Lymphoid depletion-minimal multifocal   | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Stomach                                 | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Pancreas                                | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Spleen                                  | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Testes                                  | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Prostate + seminal vesicles with coagulating glands | 10/10                                | 10/10                                  | 10/10                        | 10/10                            |
| Vagina                                  | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Urinary bladder                         | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Uterus with cervix                      | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Ovaries                                 | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |
| Rectum                                  | 10/10                                 | 10/10                                  | 10/10                        | 10/10                            |

The values shown are the number affected/number evaluated (mean severity of affected animals). The severity score shown is the highest recorded. Severity scores are out of a grade of 0 (no injury), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (extreme)

### Table 15

Summary of the presence of capsanthin in plasma and macula of Sprague-Dawley rats after 90 days of oral repeated dose of SCFE-50 C.

| Day 90 | SCFE-50 C (mg/kg BW/day) |
|--------|--------------------------|
|        | Control 500 1000 2000    |
| Capsanthin concentration ng/mL | Plasma Macula Plasma Macula Plasma Macula Plasma Macula |
| ND | ND | 0.46 | ND | 0.93 | ND | 1.8 | 0.38 |

ND: Not detected

Waters LCMS/MS equipped with MassLynx V4.1 software. Instrument conditions-mode: positive ion spray, spray source: quadrupole time of flight (QToF), desolvation gas flow: 800 L/hr., desolvation temperature: 450 ºC, source temperature: 120 ºC, capillary voltage: 2.5KV, Cone: 40 V, Cone gas flow: 50 L/hr. Isocratic mobile phase-acetonitrile and 5 mM ammonium acetate (80:20 v/v) with 0.1% formic acid. Flow rate — 0.7 mL/min. Column-Atlantis® T3 column. Dimension-4.6 × 75 mm and particle size 5 µm. The retention time for capsanthin in reference standard, capsanthin in plasma and capsanthin in macula were 7.10, 7.13 and 7.09 min respectively. The presence of capsanthin was confirmed using the m/z value of 585.51.

3.9. Organ weights, necropsy, and gross pathology findings

There were no significant changes in either absolute body weight or relative organ weight in the treated as well as control groups. Male animals in the main group showed a statistically significant decrease in absolute thyroid gland weight (G2–0.16 g, G4–0.17 g) when compared to the control group (G1–0.18 g). Also, there was an increase in brain weight in the recovery male group (2.28 g) when compared to the control group animals (2.08 g). These changes were considered as incidental as there were no supporting gross and microscopic changes. For male and female groups, body weight, the absolute and relative organ weights are shown in Table 12. For male and female recovery groups, body weight, the absolute and relative organ weights are shown in Table 13.

During necropsy, all the animals were observed for any external or internal abnormality. Gross external and internal abnormality were not observed in any of the group. External examination revealed mild focal alopecia in a few animals and is considered it to be an incidental change. However, there were no gross pathological changes in visceral organs. Besides, the cell population was found to be normal across the groups during the vaginal cytology examination in females. No variation was observed in organ weights and histological details of all female reproductive organs.

3.10. Histopathology

Histopathological examination of preserved organs collected from the vehicle control (G1) and high dose groups (G4) was examined to know the effect of the test item on these organs. Since there were no test item-related changes noted in any of the organs in the high dose group, an examination of organs from the low dose group was not carried out. Lungs showed thickening of the interstitium and peribronchial cell infiltration in a few animals from both control and high dose group with mild severity.

Only one male and female animal each from the high dose group showed moderate and severe interstitial thickening. Since the incidence of occurrence of these changes was comparable to the control group and it was considered as an incidental finding rather than test item induced. The Liver showed minimal to mild severity of hepatocellular degeneration and infiltration of inflammatory cells in both high dose and control group animals. This low severity degenerative process may be reversible as there were no signs of necrosis of hepatocytes. Further, the incidence of occurrence of degenerative changes was comparable to the vehicle control group. Also, there were no visible gross lesions in the liver and no variations in the absolute weight of the liver at the end of the recovery study period.

Kidney revealed tubular degenerative changes in a few animals from both the control and high dose groups. Administration of corn oil at the usual dose rate of 10 mL/kg as a vehicle of a test agent to rats resulted in toxic effects on the kidney. Histopathologic findings of corn oil 10 mL/kg fed male rats showed severe epithelial necrosis and fatty
degeneration of the proximal tubule and female rats showed severe fatty degeneration of proximal tubules tended to have both necrosis and basophilic tubules [27]. In this study, the tubular degenerative changes in both control and treated group may be attributed to corn oil treatment. The summary of histopathology details for male and female rats for the groups G1 and G4 is shown in Table 14.

3.11. Capsanthin levels in plasma and macula

In positive ESI mode, the presence of capsanthin was confirmed using the m/z value of 585.51. In plasma, capsanthin was not detected in the vehicle control group. In the treated groups, the capsanthin in low (G2), mid (G3) and high dose (G4) groups were 0.46 ng/mL, 0.93 ng/mL, and 1.8 ng/mL respectively. Dose-dependent increase level was seen in plasma. However, capsanthin was not detected in the macula of the Vehicle control (G1) and low dose (G2) and mid-dose (G3) groups but in the high dose group (G4) the capsanthin content was 0.38 ng/mL. The cumulative data for the capsanthin presence in plasma and eye macula for the groups G1, G2, G3, and G4 are shown in Table 15.

4. Discussion

Of late, researchers are exploring the potential biological activities of certain bioactive molecules found in commonly consumed fruits and vegetables on human wellbeing. *Capsicum annum* ethyl acetate extract protects the rat brain from rotenone-induced neurotoxicity through regulating dopamine metabolism and GSH redox [28]. Carotenoids from *Capsicum annum* are a few of the foremost chemically and functionally distinct molecules in food [29]. The unique biological properties of carotenoids such as radical scavenging, positive effect on inflammatory markers, and preventive effect of neurodegenerative disorders are due to their unique structure. The defensive role of carotenoids especially in the prevention of age-related macular degeneration [30] is well established. Capsanthin and capsorubin are the most potential antioxidant carotenoids of red bell pepper and responsible for red color [31]. While various therapeutic benefits have been reported for capsanthin, few toxicity studies were reported. The acute oral toxicity of red pepper extracts from Spanish paprika fruit with hexane on F344/DuCrj rats [32], no significant changes in general characteristics, no mortality, no change in organ weights, and no histopathological changes were observed in any experimental groups.

SCFE-50 C, a novel, first-ever red bell pepper extract enriched to capsanthin > 50% (w/w) was evaluated to confirm its toxicity in rats. No abnormalities and mortalities were observed in any group throughout the study. No change in general behavior, clinical biochemistry, hematology, urinary examination in the treated group compared to control. Analysis of serum thyroid hormone, necropsy, and histopathology examination did not reveal any statistically significant adverse events in SCFE-50 C treated groups. There were statistically significant changes in some parameters in SCFE-50 C treated groups compared to the control as given below but the clinical signs only appear during the treatment, recovers when the SCFE-50 C treatment was stopped. In male rats, a statistically significant lower body weight gain in G2, higher body weight gain in G3 were observed. In female rats, lower body weight gain in G2 were observed (Fig. 3). In male rats, a statistically significant increase in the eosinophil count in G2 and G3 when compared with the control group.

The weekly percentage mean body weight change of the vehicle control and treated groups on week six was lower (Fig. 2 & 3) and over the course of the experiment was within the acceptable range. Females showed a statistically significant decrease in WBC count in G4 and an increase in the level of platelet in G2, G3 and G4 groups compared to control group (Table 4). A statistically significant increase in the level of creatinine was observed in G3 male rats whereas the glucose level was increased in G2 female rats when compared to control group (Table 5). In G4 female rats, a significant decrease in T3 and TSH was observed (Table 8). In both control and high dose treated groups, mild severity of thickening of interstitium in lungs, hepatocellular degeneration in the liver, and tubular degenerative changes in the kidney were observed (Table 14). These changes observed were not consistent and not to be considered toxicologically significant because they are not dose-dependent and returned to normal at the end of the study period.

In summary, the findings from present animal toxicity study support the conclusion that SCFE-50 C is unlikely to cause adverse effects in SD rats. Based on the results of the 90-day study, the no-observed-effect-level (NOAEL) of saponified *Capsicum annum* fruit extract with 50% (w/w) capsanthin (SCFE-50 C) was found to be more than 2000 mg/kg BW/day, the highest dose tested.

Declaration of Competing Interest

Velmurugan Shanmugham and Ravi Subban are associated with Karpagam Academy of Higher Education, Coimbatore, India. They have been sponsored by Unibar Corporation, USA to conduct the study at the Vipragen Biosciences, India.

Acknowledgements

Our sincere thanks to Mr. Sevanti Mehta, Unibar Corporation, 13615 Morgan Creek CT Houston, TX USA 77077 for funding this study. We thank Vipragen Biosciences Pvt. Ltd, #67b, Hootagalli industrial area, Mysore, 570 018, Karnataka, India for providing the facilities to conduct this study.

References

[1] S. Kim, T.Y. Ha, I.K. Hwang, Analysis, bioavailability, and potential healthy effects of capsanthin, natural red pigment from *Capsicum* spp. Food Res. Int. 25 (2009) 198–213, https://doi.org/10.1016/S0963-9969(09)56141-0.
[2] S.N.M. Shah, S.L. Tian, Z.H. Gong, M.H. Aroha, Studies on metabolism of capsanthin and its regulation under different conditions in pepper, Fruits (Capsicum spp.) Annu. Rev. Res. Biol. 4 (2014) 1106–1120.
[3] A. Pérez-Gálvez, H.D. Martin, H. Sies, W. Stahl, Incorporation of carotenoids from paprika oleoresin into human chylomicrons, Br. J. Nutr. 89 (2003) 787–793, https://doi.org/10.1079/BJN2003842.
[4] E. Niki, Antioxidants in relation to lipid peroxidation, Chem. Phys. Lipids. 44 (1987) 227–253, https://doi.org/10.1016/0009-3084(87)90052-1.
[5] N.I. Krinsky, Antioxidant functions of carotenoids, Free Radic. Biol. Med. 7 (1989) 617–635, https://doi.org/10.1016/0891-5849(89)90143-3.
[6] B.P. Lim, A. Nagao, J. Tero, K. Tanaka, T. Suzuki, T. Takagi, Antioxidant activity of xanthophylls on epioxy-aromatic-phospholipid peroxidation, 178–184, Biochem. Biophys. Acta 1126 (92) (1992), https://doi.org/10.1016/0005-2760(92)90288-7.
[7] T. Narizawa, Y. Fukaura, M. Hasebe, S. Nomura, S. Oshima, T. Inakuma, Prevention of N-methylthiourea-induced colon carcinogenesis in rats by oxygenated carotenoid capsanthin and capsanthin-rich paprika juice, Proc. Soc. Exp. Biol. Med. 224 (2000) 116–122, https://doi.org/10.1525/1373.2000.22409.x.
[8] S.Y. Kim, J.B. Kim, I.J. Kim, Carotenoids from Capsicum annuum Fruits, protects carbon tetrachloride-induced hepatotoxicity, Food Sci. Biotechnol. 11 (2002) 537–540.
[9] H. Esterbauer, R.J. Schaur, H. Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radic. Biol. Med. 11 (1991) 81, https://doi.org/10.1016/0891-5849(91)90192-6.
[10] N.V. Medvedeva, V.A. Andrekun, A.D. Morozkin, E.A. Sergeeva, L.U. Prokoef, A.U. Misharin, Inhibition of oxidation of human blood low density lipoproteins by carotenoids from paprika, Biometel. Chem. 49 (2) (2003) 191–200.
[11] A.N.S. Panel EFSA, (EFSA Panel on Food Additives and Nutrient Sources added to Food). Scientific Opinion on the re-evaluation of paprika extract (f 160c) as a food additive, EFSA J. 13 (12) (2015) 4320, https://doi.org/10.2903/j.efsa.2015.4320.
[12] A. Joseph, N.M. Johannah, Suresh Kumar, Balu Maliakel, I.M. Krishnakumar, Safety assessment of a fenugreek dietary fiber-based formulation of capsaicinoids-rich red chilli (Capsicum annum) extract (Capsifen®): acute and sub-chronic studies, Toxicol. Rep. 7 (2020) 602–609, https://doi.org/10.1016/j.toxrep.2020.04.014.
[13] V. Shanmugham, R. Subban, Extraction of capsanthin from Capsicum annum L fruits and its effect on carboxy-ribonucleic intracellular pressure in Albino Wistar rats, J Food Biochem 45 (7) (2021), e13776 https://doi.org/10.1111/jfs.13776.
[14] Paprika extract, FAO JEPCA 16. Prepared at the 77 JEPCA, published in FAO JEPCA Monographs 14 (2013), superseding tentative specifications prepared at the
